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Objective: Ischemia-reperfusion injury is a pathologic event characterized by tissue damage. It is mediated by tumor
necrosis factor (TNF) and other cytokines that activate complement and proteases and stimulate fibrinolysis, degranu-
lation of white blood cells, and free radical production. We recently reported that vagus nerve stimulation (VNS)
suppresses endotoxin-induced cytokine synthesis through  bungarotoxin-sensitive cholinergic receptors. VNS protects
against endotoxin-induced shock by inhibiting hepatic and cardiac synthesis of TNF. Here, the effects of VNS on
suppression of ischemia-reperfusion injury and cytokine release were studied in a rat model of aortic occlusion.
Methods: Adult male Lewis rats were subjected to laparotomy and suprarenal aortic clamping for 15 minutes followed by
reperfusion. Blood pressure, heart rate, and respiratory rate were recorded every 3 minutes for 90 minutes. Exposed
cervical vagus nerves in the experimental group were stimulated for 5 minutes before and after aortic occlusion, with
constant voltage (1 V, 2 ms, 5 Hz); sham-operated animals received no stimulation. TNF levels in serum and organs were
measured with enzyme-linked immunosorbent assay ELISA (BioSource International, Camarillo, Calif). Data analysis
was performed with the Student t test.
Results: Control animals had shock develop (mean, 59% decrease in blood pressure) whereas blood pressure in the
stimulated animals did not decrease (control versus stimulated animals, P < .05). VNS significantly inhibited TNF levels
in serum (7  1 ng/mL versus 45  6 ng/mL; P  .0008), heart (21  11 ng/g protein versus 85  15 ng/g protein;
P  .01), and liver (16  2 ng/g protein versus 42  12 ng/g protein; P  .02).
Conclusion: VNS significantly attenuates TNF synthesis and shock during reperfusion injury in a standard model of aortic
occlusion. Clinical evaluation of VNS for this condition may be warranted. (J Vasc Surg 2002;36:1231-6.)
There is no effective treatment for reperfusion injury
after ischemia. Tissue damage occurs when blood flow is
restored and toxic substances are released systemically.
Proinflammatory cytokines (tumor necrosis factor [TNF],
interleukin-1, interleukin-6, and interleukin-18) play a
critical role in the pathogenesis of ischemia-reperfusion
(IR), and TNF is a proximal mediator of cytokine release.
The primary source of circulating TNF released during
systemic inflammation is resident macrophages in liver and
other organs.1,2 High TNF levels mediate myocardial de-
pression, vasodilation, extravascular fluid sequestration, hy-
potension, adult respiratory distress syndrome, and multi-
system organ failure. Cytokine inhibitors have been
developed as experimental therapeutics to treat IR and
sepsis-related organ failure.3,4 We recently discovered that
cytokine synthesis is inhibited by activation of the cholin-
ergic antiinflammatory pathway (CAP) and that vagus
nerve stimulation (VNS) confers significant protection
against lethal endotoxemia.5 The CAP, which can be acti-
vated chemically or electrically, effectively suppresses sys-
temic TNF release and attenuates organ damage. VNS is a
safe clinical tool currently used for the treatment of epilepsy
and depression.6,7 Here we evaluated the effects of VNS on
TNF production and hypotension after IR after acute aortic
occlusion.
MATERIALS AND METHODS
Animals. Adult male Lewis rats (225 to 250 g,
Charles River Laboratories, Wilmington, Mass) were
housed at 25° C on a 12-hour light/dark cycle. Standard
rat chow and water were freely available. All animal exper-
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iments were performed in accordance with the Guide for
the Care and Use of Laboratory Animals, Institute of
Laboratory Animal Resources, Commission on Life Sci-
ences, National Research Council Washington, under pro-
tocols approved by the Institutional Animal Care and Use
Committee of North Shore University Hospital and New
York University Medical School. Animals were anesthe-
tized with urethane (1.0 gm/kg, intraperitoneal) and xyla-
zine (10 mg/kg intramuscular).
Electric stimulation of the cervical vagus nerve.
The left cervical vagus nerve trunk was exposed and isolated
from surrounding tissue with a small piece of parafilm. The
nerve was placed on stimulating bipolar platinum elec-
trodes (Plastics One, Roanoke, Va). The electrodes were
connected to a single channel stimulation amplifier module
(Biopac Systems STM 100A, Santa Barbara, Calif) with a
stimulus isolator adaptor (STMISO, Harvard Apparatus,
Inc, Holliston, Miss), to provide an isolated voltage stim-
ulus to the nerve. One volt (2 ms, 5 Hz) stimulation was
applied 5 minutes before and after aortic clamping, for a
total of 10 minutes of stimulation. Rats were subjected to
left VNS or sham operation. Sham-operated animals under-
went left cervical vagus nerve exposure without stimula-
tion.
IR. After left cervical vagus nerve exposure, the right
common carotid artery was cannulated with a 24-gauge
angiocatheter for blood pressure recording. The catheter
was connected to a blood pressure transducer and an Ac-
quisition System (MP 100, Biopac Systems) for continuous
registration of mean arterial blood pressure. A left retroper-
itoneal approach was used to expose the abdominal aorta.
The suprarenal aorta was controlled with a 2-0 prolene
suture. The right common femoral vein was cannulated
with a 24-gauge angiocatheter, and appropriate resuscita-
tion was administered with normal saline solution (0.9%) at
4.0 mL/kg/h. After 20 minutes of stabilization, the ani-
mals were systemically heparinized (100 units/kg) and the
suprarenal aorta was clamped for 15 minutes. Mean arterial
blood pressure, heart rate, and respiratory rate were re-
corded in 3-minute intervals, beginning 20 minutes before
and ending 120 minutes after aortic clamping.
At the completion of monitoring, animals were killed
and serum was collected. The heart, liver, lung, and kidneys
were rapidly excised, rinsed of blood, homogenized with
polytron (Brinkman, Muskegon, Mich) in homogenization
buffer (phosphate-buffered saline solution, containing
0.05% Triton X-100 and a protease inhibitor cocktail; pH,
7.2; 4° C), and sonicated for 10 minutes. Homogenates
were centrifuged at 12,000g for 10 minutes, and TNF was
measured with enzyme-linked immunosorbent assay (Bio-
source International, Camarillo, Calif). Liver, lung, heart,
and kidney TNF were normalized to the protein concen-
tration in the sample.
Statistical analysis. All data in the figures and text are
expressed as the mean the standard error of the mean for
five animals per group. The Student t test was used to
compare mean values between groups.
RESULTS
Attenuation of hypotension/shock. Our previous
studies showed that pharmacologic or electrical stimulation
of the vagus nerve attenuates systemic and organ TNF
expression increases heart rate and prevents the develop-
ment of lethal hypotension in response to endotoxin infu-
sion.8,9 Because IR injury shares many pathologic mecha-
nisms in common with sepsis and endotoxemia, we chose
to evaluate the efficacy of VNS in rats subjected to supra-
renal aortic clamping. Electrical stimulation (1 V, 5 Hz, 2
ms pulse rate) was applied to the vagus nerve for 5 minutes,
with no change in blood pressure or respiratory dynamics
during cervical VNS observed in either group (Fig 1). The
suprarenal abdominal aorta was clamped, and electrical
Fig 1. Percent mean arterial blood pressure versus time. Animals were subjected to VNS or sham procedure before
aortic clamping. VNS prevented development of hypotension (P  .05 at 120 minutes).
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stimulation of the vagus nerve was continued for 5 minutes;
the aortic clamp was left in place for an additional 10
minutes. Mean blood pressure transiently increased by 60%
on aortic clamping in both groups. The sham-stimulated
group had a significant drop in blood pressure that per-
sisted throughout reperfusion; the final blood pressure was
38% of baseline (P  .05). Stimulated animals were pro-
tected from hypotension and maintained baseline blood
pressure throughout the reperfusion interval.
Voltage-dependent response. To evaluate the effects
of VNS with different voltages on hemodynamic responses
to IR injury, animals were subjected to suprarenal aortic
clamping, and electrical stimulation of the cervical vagus
nerve was performed with 0.1 or 0.5 V. As shown in Fig 2,
protection against lethal hypotension was voltage dose-
dependent. VNS at 0.05 V significantly attenuated the
development of hypotension at 120 minutes (P  .05).
VNS at 0.01 V failed to prevent hypotension, indicating
that the VNS voltage is specific.
VNS attenuates TNF levels. TNF is a well-char-
acterized proximal mediator of inflammation during
endotoxemia, sepsis, and IR injury. To determine the ef-
fects of VNS on systemic and organ TNF expression, ani-
mals were subjected to 15 minutes of ischemia and 90
minutes of reperfusion. Serum and organs then were col-
lected for determination of TNF. VNS (1 V, 5 Hz, 2 ms
pulse width) significantly attenuated TNF expression in
liver, serum, and heart as compared with sham-stimulated
control animals (P  .05; Fig 3). VNS significantly inhib-
ited cardiac TNF, suggesting that this approach can mod-
ulate IR-induced cardiac TNF synthesis. There was no
significant effect of VNS on pulmonary or renal TNF (Fig
4), indicating that inhibition of hepatic and cardiac TNF by
VNS is specific.
Fig 2. Voltage dose response and mean arterial blood pressure. Hypotension was prevented by VNS at 0.5 V but not
at 0.1 V (P  .05 at 120 minutes).
Fig 3. Hepatic, serum, and cardiac TNF levels. Serum and organs were prepared as described and collected 120
minutes after aortic clamping (*P  .05).
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DISCUSSION
These results indicate that electrical stimulation of the
CAP can modulate the cytokine response to IR. By inhib-
iting the production of TNF through VNS, it is possible to
attenuate IR-induced shock. The clinical syndrome of IR is
a challenging problem because few treatment options are
available to prevent the development of significant systemic
inflammatory responses. We have demonstrated that the
over-expression of TNF during sepsis in rats can be modu-
lated by the CAP.8 The central nervous system inhibits
inflammation via the vagus nerve, a critical pathway for
neural regulation of cytokine synthesis. VNS in rats ex-
posed to endotoxin (lipopolysaccharide) attenuated serum,
liver, and heart TNF and the development of shock.5 Aortic
surgery requires temporary clamping, leading to the pro-
duction of cytokines (IL-1, IL-6, IL-8, TNF).10-13 Rup-
tured abdominal aortic aneurysms stimulate systemic in-
flammation and lead to increased TNF.14-16
The levels of serum TNF at the end of reperfusion (120
minutes) were significantly higher in unstimulated control
animals as compared with vagus nerve–stimulated animals.
The TNF levels in heart and liver were also elevated in the
control animals. These findings suggest that IR upregulates
TNF synthesis in heart and liver. TNF production is maxi-
mal during the ischemia and early reperfusion period and
then declines during subsequent reperfusion and ap-
proaches baseline (data not shown). VNS attenuated TNF
during both the early (15 minutes) and later (90 minutes)
stages of reperfusion, indicating that VNS inhibits TNF
synthesis.
There was an inverse relationship between hypotension
and TNF levels in the control animals, suggesting that TNF
may contribute to the development of shock. VNS pre-
vented shock without decreasing heart rate. Other hemo-
dynamic or respiratory morbidities related to VNS were not
observed, in agreement with the clinical experience using
VNS. These data are consistent with previous studies of
VNS to attenuate TNF production in animals exposed to
lipopolysaccharide-induced shock.5 Future studies of VNS
and prevention of IR-related shock will address additional
hemodynamic monitoring, the evaluation of other cyto-
kines, and tissue pathology. There are no effective thera-
peutic measures for the prevention and treatment of IR
after aortic surgery or cases of acute arterial occlusion.
These data indicate that additional preclinical studies and
perhaps clinical evaluation of VNS for treatment of cyto-
kine-mediated inflammatory syndromes is warranted.
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DISCUSSION
Dr Michael T. Watkins (Boston, Mass). Dr Brener, mem-
bers of the Society, and Dr Bernik. I would like to preface my
discussion of this paper by mentioning that many times a good
scientific investigation will ask more questions than it will answer.
Now, the scientific basis for this work was published in the Nature
Medicine journal and the Journal of Experimental Medicine;
therefore, there is no question regarding the scientific sophistica-
tion of the study. Bernik and associates present data that suggest
that cholinergic neural transmission via vagal nerve stimulation can
inhibit the hemodynamic and inflammatory components of isch-
emia and reperfusion injury. Based on the data from enzyme-
linked immunosorbent assay, the authors conclude that vagal nerve
stimulation decreases cytokine synthesis in the heart and liver after
a brief suprarenal aortic cross clamp. These data are intriguing
because they provide insight into the often-overlooked neurogenic
component of the response to injury. Furthermore, the data in the
paper provide a radical departure from the usual approaches to
ameliorate reperfusion injury. There is no discussion of antineu-
trophil antibodies, prostaglandin analogues, nitric oxide inhibi-
tors, and scavengers of reactive oxygen metabolites. While the data
are convincing, several important questions must be addressed:
1. Can you comment on the nature of parasympathetic blockade
or activity in the rat? Why did vagal stimulation fail to decrease
heart rate or blood pressure, particularly prior to aortic cross
clamping? Is vagal stimulation in the rat comparable to vagal
stimulation in humans? Can a dose-response curve be generated
between the degree of vagal stimulation and changes in blood
pressure and heart rate? Does atropine obliterate the protective
effect of vagal stimulation, or can administration of an acetyl-
choline mimetic provide the same degree of protection as the
nerve stimulator?
2. Can you explain the rationale for beginning the vagal nerve
stimulation before the onset of aortic cross clamping? Do you
see the same protective effect if the vagal nerve stimulation is
applied after the aortic crossclamp is applied?
3. Is there any chance that ischemic bowel or endotoxin actually
plays a role in your model? According to your manuscript, you
approach the rat aorta from a retroperitoneal approach, which is
fairly challenging. Is it possible that the surgical approach you
have taken compromises the bowel during either the exposure
or the cross clamp? I would not expect this degree of hypoten-
sion associated with a suprarenal clamp. If even 15 minutes of
bowel ischemia developed, endotoxemia caused by transient
bowel ischemia might be the root of the circulatory shock in this
animal.
4. Since the sympathetic and parasympathetic systems are physio-
logically opposed to one another, is it possible that the vagal
stimulation that you have provided is the physiologic equivalent
to -adrenergic blockade? As you know, -adrenergic blockade
is routinely used to manage blood pressure and heart rate in
humans undergoing major vascular surgery. Is it possible that
-adrenergic blockade tips the neurogenic balance so that there
may be relatively increased vagal tone? Can pharmacologic 
blockade provide a similar benefit with respect to tissue TNF
content and hemodynamic stability?
This paper presents a novel perspective on the management of
a challenging clinical problem. The authors are to be commended
on their approach to this problem, and I thank the Program
Committee and this Society for the privilege of discussing this
provocative paper.
Dr Thomas R. Bernik. When vagus nerve stimulators are
used in clinical practice, a continuous wave of approximately 1 to 5
V is used. It does not appear to affect heart rate or blood pressure.
We used similar voltages in this model. Using 1 and 5 V produced
no difference in blood pressure response. When we looked at heart
rate, however, we were surprised to find that it did not increase in
the sham group of animals. In the stimulated group, the heart rate
increased significantly in a dose response manner; this may be due
to direct suppression of cardiac TNF production. We also looked at
whether stimulating the right versus left vagus nerve made a
difference, knowing that the nerves innervate the heart and body
organs differently. Stimulation of both sides demonstrated no
significant difference in laterality.
In a similar model investigating the effects of CNI-1493, an
antiinflammatory compound that blocks inflammation through
the vagus nerve, we found that atropine abrogates the compound’s
protective effects. In other words, atropine causes a chemical
vagotomy and produces the same effect seen with mechanical
vagotomy. We need to repeat this test in the ischemia-reperfusion
model.
Our model was selected with the need for completion of
experiments within 3 hours and early induction of profound reper-
fusion injury. After trial and error, this model of suprarenal clamp-
ing worked best. I did not want to clamp proximal to the celiac
access for fear of bowel and liver ischemia, and I do not think that
bowel ischemia played a role in this experiment.
The TNF levels that we measured in the heart and in the lung
were close to twice those in the liver. One would have to measure
TNF receptors in each organ to establish whether this is truly
primary cardiac and lung production or circulating TNF. I think
we are seeing some systemic TNF, with the majority produced by
heart.
 Blockade decreases the oxygen demand in the heart by
decreasing heart rate and contractility. Other proposed mecha-
nisms of the beneficial effects of  blockade on ischemia are that it
decreases lipolysis and elevates the threshold for ventricular fibril-
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lation. I think that the mechanism of action in this study is
different. By decreasing cardiac and systemic TNF, which is a
negative inotrope and cardiac depressant, we are permitting for
normal cardiac function. That is why we are seeing a paradoxic
increase in heart rate in the stimulated group compared to the
decrease in heart rate observed in the sham animals during the later
stages of shock.
Dr Gary A. Fantini (New York, NY). Could you educate us
as to the dynamic of TNF generation. Specifically, is there evidence
that ischemia generates message for TNF production that rapidly,
or are the increased levels you observed in the absence of vagal
stimulation thought to be due to the release of preformed TNF?
My second question relates to potential clinical application. As
I understand the model, vagal stimulation occurred prior to and
following aortic clamping. In terms of utility in the clinical setting,
vagal stimulation would need to follow the onset of ischemia, and
I am wondering if you did experiments in that fashion?
Dr Bernik. The cholinergic antiinflammatory pathway repre-
sents a rapid neural response to injury or infection. The vagus nerve
innervates many organs, and as soon as the brain receives afferent
input, efferent signals are sent to these organs, which causes
acetylcholine release and suppression of TNF production.
We have also performed in vitro studies on macrophage cul-
tures, which showed decreased TNF production from macro-
phages in the presence of acetylcholine, nicotine, and other cho-
linergic agonists.
With respect to when we decided to give the vagus nerve
stimulation, we need to determine if this potential therapeutic can
be administered prior to an injury and what kind of memory an or-
ganism has for nerve stimulation. These experiments are in progress.
CORRECTION
In: “Comparison of the resistance to infection of rifampin-bonded gelatin-sealed and silver/collagen-
coated polyester prostheses” (Goe¨au-Brissonnie`re OA, Fabre D, Leflon-Guibout V, Di Centa I, Nicolas-
Chanoine M-H, Coggia M. J Vasc Surg 2002;35:1260-3).
On page 1260, in the “Materials” portion of the “Materials and Methods” section, it is currently stated that the
rifampin concentration of the solution in which the rifampin-bonded gelatin-sealed prostheses were soaked was 60
mg/L. This is incorrect and should read 60 mg/mL instead.
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